Bénéfice à l'évaluation moléculaire en routine pour les cancers bronchiques métastatiques

An actionable oncodriver was routinely detected in nearly half of patients with advanced lung adenocarcinoma. This systematic detection may influence treatment outcomes, notably with matched targeted therapy.